 REMoDLB is a trial which aims to determine whether the addition of bortezomib a drug that blocks the action of cellular complexes that break down proteins to standard combination chemotherapy called R-CHOP improves how long patients with diffuse large B cell lymphoma survive without a recurrence of the disease. Results from recent research have suggested that patients can be divided into two biologically distinct subgroups labeled GCB germinal centre derived B-cells like and ABC activated peripheral B-cells like. 